{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:54Z","timestamp":1786119354485,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/mbc.0b013e328329f265","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T06:22:32Z","timestamp":1242886952000},"page":"225-229","source":"Crossref","is-referenced-by-count":27,"title":["Anaphylaxis in patients with congenital bleeding disorders and inhibitors"],"prefix":"10.1097","volume":"20","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zaffanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Salvagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna Franca","family":"Rivolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Di Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/01.moh.0000130312.87668.bf","article-title":"Factor VIII alloantibodies in hemophilia","volume":"11","author":"Jacquemin","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH07-10-0592","article-title":"Plasma-derived biological medicines used to promote haemostasis","volume":"99","author":"Ofosu","year":"2008","journal-title":"Thromb Haemost"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2000-9824","article-title":"Anaphylaxis in patients with hemophilia","volume":"26","author":"Jadhav","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM196908072810617","article-title":"Reaction to rapidly infused AHF cryoprecipitate","volume":"281","author":"Clapp","year":"1969","journal-title":"N Engl J Med"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0002-9343(80)80026-X","article-title":"Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia","volume":"69","author":"Helmer","year":"1980","journal-title":"Am J Med"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1537-2995.1988.28689059042.x","article-title":"Anaphylactic reaction to purified antihemophilic factor concentrate","volume":"26","author":"Bove","year":"1988","journal-title":"Transfusion"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1055\/s-0038-1649877","article-title":"Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor","volume":"74","author":"Harper","year":"1995","journal-title":"Thromb Haemost"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1537-2995.1996.36496226153.x","article-title":"Anaphylaxis after treatment with recombinant factor VIII","volume":"36","author":"Shopnick","year":"1996","journal-title":"Transfusion"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2516.2006.01339.x","article-title":"IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A","volume":"13","author":"Kadar","year":"2007","journal-title":"Haemophilia"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s004310050774","article-title":"Anaphylactic response to factor VIII preparations in a haemophilic child with an inhibitor of high titre during the tolerance induction","volume":"157","author":"Tsuchiya","year":"1998","journal-title":"Eur J Pediatr"},{"key":"R13-2-20210203","first-page":"143","article-title":"Anaphylaxis following the use of a plasma-derived immunopurified monoclate-P, and the recombinant Recombinate and Kogenate factor VIII: a therapeutic challenge","volume":"5","author":"Pernod","year":"1999","journal-title":"Haemophilia"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/s-0038-1645053","article-title":"Lack of immune response to mouse IgG in hemophilia A patients treated chronically with monoclate, a monoclonal antibody affinity purified factor VIII preparation","volume":"63","author":"Davis","year":"1990","journal-title":"Thromb Haemost"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2222.1979.tb00485.x","article-title":"IgG4: a possible mediator of anaphylaxis in a haemophiliac patient","volume":"9","author":"Shakib","year":"1979","journal-title":"Clin Allergy"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood.V75.2.378.378","article-title":"Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients","volume":"75","author":"Nilsson","year":"1990","journal-title":"Blood"},{"key":"R17-2-20210203","first-page":"215","article-title":"Desensitization to factor VIII in a patient with classic hemophilia and C2 deficiency","volume":"58","author":"Jamieson","year":"1987","journal-title":"Ann Allergy"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2516.1998.440574.x","article-title":"Management of haemophilia B patients with inhibitors and anaphylaxis","volume":"4","author":"Warrier","year":"1998","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"R19-2-20210203","first-page":"S125","article-title":"Development of anaphylactic shock in haemophilia B patients with inhibitors","volume":"9","author":"Warrier","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00043426-199701000-00003","article-title":"Factor IX inhibitors and anaphylaxis in hemophilia B","volume":"19","author":"Warrier","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.1999.t01-1-00303.x","article-title":"Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk","volume":"5","author":"Thorland","year":"1999","journal-title":"Haemophilia"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1046\/j.1365-2516.1998.00190.x","article-title":"Anaphylactoid reactions and nephrotic syndrome: a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers","volume":"4","author":"Tengborn","year":"1998","journal-title":"Haemophilia"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1365-2516.2000.00419.x","article-title":"Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure","volume":"6","author":"Barnes","year":"2000","journal-title":"Haemophilia"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2516.2001.0538c.x","article-title":"Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report","volume":"7","author":"Barnes","year":"2001","journal-title":"Haemophilia"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MPH.0b013e31815cf742","article-title":"Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis","volume":"30","author":"Alexander","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2516.2003.00772.x","article-title":"Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates","volume":"9","author":"Shibata","year":"2003","journal-title":"Haemophilia"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-2516.2007.01463.x","article-title":"Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction","volume":"13","author":"Curry","year":"2007","journal-title":"Haemophilia"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MBC.0b013e3282f2b5fd","article-title":"The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate","volume":"19","author":"Chuansumrit","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0049-3848(96)00136-3","article-title":"Measurement of antifactor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates","volume":"83","author":"Sawamoto","year":"1996","journal-title":"Thromb Res"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0091-6749(98)70061-2","article-title":"IgE-mediated allergy and desensitization to factor IX in hemophilia B","volume":"102","author":"Dioun","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM198804143181503","article-title":"Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII","volume":"318","author":"Nillson","year":"1988","journal-title":"N Engl J Med"},{"key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V89.3.1115","article-title":"Nephrotic syndrome as a complication of immune tolerance in hemophilia B","volume":"89","author":"Ewenstein","year":"1997","journal-title":"Blood"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/262141a0","article-title":"Precipitating antibodies in von Willebrand's disease","volume":"262","author":"Mannucci","year":"1976","journal-title":"Nature"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI112974","article-title":"Gene deletions correlate with the development of alloantibodies in von Willebrand disease","volume":"79","author":"Shelton-Inloes","year":"1987","journal-title":"J Clin Invest"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0037-1613799","article-title":"Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease","volume":"83","author":"Tout","year":"2000","journal-title":"Thromb Haemost"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V57.1.25.25","article-title":"Precipitating antibodies to factor VIII\/von Willebrand factor in von Willebrand's disease: effects on replacement therapy","volume":"57","author":"Mannucci","year":"1981","journal-title":"Blood"},{"key":"R38-2-20210203","first-page":"348","article-title":"Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"J Lab Clin Med"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002770050323","article-title":"Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor\u2013factor VIII interaction","volume":"75","author":"Batlle","year":"1997","journal-title":"Ann Hematol"},{"key":"R40-2-20210203","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","article-title":"Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor","volume":"39","author":"Mannucci","year":"1987","journal-title":"Eur J Haematol"},{"key":"R41-2-20210203","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2516.2008.01668.x","article-title":"Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report","volume":"14","author":"Franchini","year":"2008","journal-title":"Haemophilia"},{"key":"R42-2-20210203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1538-7836.2003.00009.x","article-title":"Multitherapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease","volume":"1","author":"Boyer-Neumann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"R43-2-20210203","first-page":"150","article-title":"Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor","volume":"26","author":"Ciavarella","year":"1996","journal-title":"Haemostasis"},{"key":"R44-2-20210203","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0037-1613878","article-title":"Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor","volume":"83","author":"Grossmann","year":"2000","journal-title":"Thromb Haemost"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001721-200906000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:58:29Z","timestamp":1786039109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200906000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e328329f265","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}